Navigation Links
BioInformatics, LLC Studies Trade Show Exhibition Strategies in the Life Science Market
Date:2/28/2008

s were asked to identify which conference organizers have the best exhibit halls. The American Association for Cancer Research and the Society for Neuroscience were ranked tops by both scientists and vendors; however, scientists and vendors reported different opinions with regard to 3rd and 4th place exhibit halls.

"While the top two choices were the same for both vendors and scientists, it's important to note that no single entity received the majority of votes for best exhibit hall," stated Dr. Zemlo. "Additionally, while write-in answers for the organizer of the best exhibit hall comprise 24% of vendors' answers, they constitute 41% of scientists' answers, reflecting the wide variety of conference options available to scientists."

This invaluable report provides suppliers and conference organizers with a roadmap for implementing a successful exhibition strategy. In "The Scientist Perspective" section, the beliefs and attitudes of 1,000 life scientists are featured, including how they select and why they attend scientific conferences as well as their expectations for exhibit halls. This section also provides information intended to help vendors attract scientists to their exhibit booths and tips to increase lead generation. In "The Vendor Perspective" section, marketing and sales executives from life science companies share their insights on how they select conferences to attend, exhibit and sponsor. This section also describes how vendors measure their conference ROI and how the emergence of new media may affect the future of trade show exhibiting.

"Conferences & Exhibits in the Life Sciences: What's Working Now" includes over 50 charts, tables and cross-tabulations of the survey data. For a complimentary Executive Summary of this report, please visit http://www.gene2drug.com/report/189/

ABOUT BIOINFORMATICS, LLC

BioInformatics, LLC is the premier research and advi
'/>"/>

SOURCE BioInformations, LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
2. Caliper Life Sciences Introduces High Throughput RNA Assay to Improve Workflow in Gene Expression Studies
3. Sigma-Aldrich and the Universite de Montreal Establish Collaboration for RNA Interference Studies
4. Argonne researcher studies what makes quantum dots blink
5. Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
6. AIM-Quoted Verona Pharma Progresses Anti-Asthma Drug Studies
7. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
8. Promising Data ATIR Studies Presented by NIH Investigators
9. Clemson researcher studies carbon fibers for nuclear reactor safety
10. 2007 a "Record Year" for Successful Validation Studies of Simbionix Simulators
11. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... and BOSTON , Oct. ... ), a leading global specialty pharmaceutical company, and Rhythm, ... granted an exclusive option to acquire Rhythm,s wholly owned ... a peptide ghrelin agonist, for the treatment of diabetic ... Rhythm has completed a successful Phase 2 trial of ...
(Date:10/22/2014)... Involution Studios , a healthcare software ... infographic, Understanding Ebola . The goal of ... to follow informative tool for anyone wanting to know ... prevention. , "As the news has spread in all ... represents not only a healthcare crisis with global impact, ...
(Date:10/22/2014)... SC (PRWEB) October 22, 2014 ... of its cardiovascular pharmacogenetics menu, which enables healthcare ... outcomes. With PCLS’s evidence-based results, healthcare providers ... and optimize their therapy, while minimizing risks for ... the U.S., according to the FDA [1] more ...
(Date:10/22/2014)... , Oct. 22, 2014 Nuvilex, Inc. ... approximately 400 million people worldwide are living with diabetes, ... people by 2030.  The global market for diabetes treatments ... approximately 330,000 people worldwide died from pancreatic cancer.  Pancreatic ... due to cancer in the United States ...
Breaking Biology Technology:Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2
... Longer-term Phase 2 Switching Study, CRANBURY, ... company developing small-molecule, orally administered,pharmacological chaperones for ... that the Company will present positive results ... (isofagomine tartrate) for Gaucher disease,at the American ...
... on the strangeness of the nanoworld, researchers at the ... University of Maryland-College Park have discovered that materials such ... behave as ductile as gold at the nanoscale. Their ... NIST scientists Pradeep Namboodiri and Doo-In Kim and colleagues ...
... Calif., March 12 ,Exelixis, Inc. (Nasdaq: EXEL ) ... executive officer of Exelixis, will present at the,Cowen and ... / 1:00 p.m.,PT on Monday, March 17, 2008. Dr. ... corporate strategy., The presentation will be webcast and ...
Cached Biology Technology:Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease 2Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease 3Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease 4Nanomaterials show unexpected strength under stress 2
(Date:10/15/2014)... Oct. 15, 2014   Neurotechnology , a ... the availability of the VeriLook Surveillance 3.0 ... provides real-time biometric face identification using live video ... cameras. The new version not only identifies faces ... from objects while they are moving through the ...
(Date:10/14/2014)... house fly genome for the first time, revealing robust ... that thrives in pathogen-rich dung piles and garbage heaps. ... Genome Biology , will increase understanding of house ... adapt to resist insecticides, which could lead to novel ... and transmit more than 100 human and animal diseases, ...
(Date:10/14/2014)... LA JOLLA, CA – October 14, 2014 – Scientists ... $6.6 million from the National Institutes of Health (NIH) ... most prevalent virus-induced hemorrhagic fever disease in Africa. The ... disease and why some patients die, while others survive ... researchers to understand the basic mechanism of how Lassa ...
Breaking Biology News(10 mins):VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3House fly genome reveals expanded immune system 2Scripps Research Institute team receives $6.6 million to investigate deadly Lassa virus 2
... anachronism? Or is it a vital part of a ... 2.4 billion more people by the year 2050, the drive ... , But there,s an important downside to this trend, argues ... Montreal, in a paper to be presented Saturday, Feb. 15, ...
... Calif.) When mothers feed their newborns formula in the ... in the second month of life and more likely to ... longer, UC Davis researchers have found. "We are ... hospital can cause problems by reducing how much women breastfeed ...
... Rochelle, NY, February 13, 2014Food spoiling and poisoning caused ... economic problems. The broad scope of antimicrobial approaches to ... and beverages, including a variety of natural and artificial ... in Industrial Biotechnology , a peer-reviewed journal from ...
Cached Biology News:Making biodiverse agriculture part of a food-secure future 2Making biodiverse agriculture part of a food-secure future 3In-hospital formula use deters breastfeeding 2In-hospital formula use deters breastfeeding 3
... Ambion's ActivePro In ... from an E.coli lysate, ... protein as well as ... activity than competing kits. ...
... Mouse Serum • Mouse serum is collected off ... and 8-12 weeks of age. Available Anticoagulants: ... N-06: K2EDTA N-08: Potassium Oxalate ... N-05: ACD N-07: CPD ...
GeneRacer is an advanced RACE (rapid amplification of cDNA ends) technique that improves the efficiency of amplifying full-length 5' and 3' cDNA ends. With the GeneRacer Kit you can:...
One-step, microplate or cuvet, colorimetric, linear detection range 0.6 mM to 100 mM. Procedure: 2 min....
Biology Products: